MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MDR - MEDADVISOR LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -5.54
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.54

19 Jul
2024

-0.010

OPEN

$0.54

-1.82%

HIGH

$0.55

202,007

LOW

$0.51

TARGET
$0.49 -9.3% downside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MDR: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 2.1 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 1100.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-2.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx98.0 M
Book Value Per Share xxxxxxxxxxxxxxx11.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-1.5 M
Net Profit Margin xxxxxxxxxxxxxxx-11.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-27.24 %
Return on Invested Capital xxxxxxxxxxxxxxx-21.89 %
Return on Assets xxxxxxxxxxxxxxx-12.97 %
Return on Equity xxxxxxxxxxxxxxx-27.24 %
Return on Total Capital xxxxxxxxxxxxxxx-14.09 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx12 M
Total Debt xxxxxxxxxxxxxxx13 M
Goodwill - Gross xxxxxxxxxxxxxxx47 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx14 M
Price To Book Value xxxxxxxxxxxxxxx2.27

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx0.18 %
Cost of Goods Sold xxxxxxxxxxxxxxx85 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

01/03/2024

-1

No Rating

-

Morgans offers no 12-month target or rating for MedAdvisor, but is keeping tabs on the company's progress, including a review of yesterday's 1H result, which proved in line with forecasts as numbers had been pre-released.

The gross margin fell by -240bps on the previous corresponding period to 57.6% due to a higher share of lower-margin revenue in traditional health communications programs in the US, explains the analyst.

Investment into the UK has completed, as has the transition to the SaaS platform, notes the broker.

Management is aiming to optimise a cloud-native platform by investing in a shared service structure, which should reduce operating costs over time, observes Morgans.

Management is guiding to profitability in FY24.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

29/05/2024

1

Buy

$0.45

-16.67%

Canaccord Genuity analysts have maintained their Buy rating for MedAdvisor and raised their price target to $0.45 from $0.39 on a stronger-than-anticipated trading update.

The broker noted the latest trading update revealed management's revenue expectations of $120m-$123m, beating the prior estimate of $114.5m.

EBITDA guidance has also improved to $6.8m-$7.6m from a previously expected $3.5m. The broker attributes the revenue beat to strong performance in the US and Australia, particularly from the THRiV omnichannel product.

FY25 revenue now expected to reach $143.9m with EBITDA forecasted at $8.2m.

FORECAST
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.00 cents.
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.

MDR STOCK CHART